Alternative approaches to OSA treatment have become highly appealing with the advent of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), incretin-based drugs that have revolutionised obesity management. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.